Sun Pharmaceutical Industries Limited — PPTs, 14-07-2025: Investor Presentation

**Financial Highlights:**

Sun Pharma reported strong FY25 performance with sales of ₹52,000 Cr, up 9% year-over-year, and Adjusted Net Profit increasing by 19% to ₹11,984.4 Cr. Profitability remained robust, with EBITDA margin at 29% and Gross Margin at 79.3%. The company maintains a healthy balance sheet with ₹11,331.6 Cr in cash and low gross debt of ₹1,869.6 Cr.

**Strategic Initiatives & Growth Drivers:**

The company is focused on increasing contribution from innovative and complex specialty products, supported by R&D investments at 6.2% of sales. Strategic objectives include optimizing operational costs, achieving critical market mass, and embedding sustainability. Management targets mid-to-high single-digit consolidated top-line growth for FY26.

**Business Developments:**

Recent strategic moves include the acquisition of Checkpoint Therapeutics, enhancing its anti-cancer immunotherapy portfolio, and completing the Taro merger to make it a 100% subsidiary. Key product launches like Sezaby and Winlevi in the US underscore its expanding specialty portfolio.

**Market Position & Competitive Advantage:**

Sun Pharma is the largest pharmaceutical company in India with an 8.3% market share and ranks #1 for 13 prescriber categories. It is also the 12th largest generics player in the US. Its diversified revenue streams across geographies and therapies, coupled with best-in-class profitability, provide a strong competitive edge.

**Investor Implications:**

The consistent financial growth, strategic acquisitions, and focus on high-margin specialty products point towards positive growth potential. Sun Pharma's diversified business model and market leadership positions offer a stable outlook for investors.